For research and educational purposes only. Not medical advice.

Goserelin Reference

Educational, not medical advice reference for Goserelin: Reproductive, Hormonal; regulatory status, evidence posture, source review, and schedul…

Reference summary

Goserelin is a decapeptide GnRH agonist with decades of approved-label oncology and gynecology evidence. After a brief LH/FSH surge it desensitizes the pituitary, producing reversible medical castration. The 3.6 mg one-month and 10.8 mg three-month implants are interchangeable depot formats. Bone mineral density loss, hot flashes, and metabolic shifts are well-characterized in long-duration label use; in men a tumor-flare phenomenon during the first 1-2 weeks is a known label concern that drives concurrent antiandrogen coverage at initiation in advanced prostate cancer.

Regulatory and posture

Categories
Reproductive, Hormonal
Aliases
Zoladex, GnRH agonist depot implant, ICI 118630
Evidence posture
human - Oncology / gynecology drug. Prescription-only and clinician-administered (depot implant inserted with a wide-bore needle); off-label or self-administered use is not safe. Tumor flare during the initial surge phase is a labeled risk in advanced prostate cancer.
Regulatory status
FDA-approved prescription medication (Zoladex). Indications include advanced prostate cancer (often combined with an antiandrogen for medical castration), early-stage hormone-receptor-positive breast cancer in pre- and perimenopausal women, palliative breast cancer, endometriosis, endometrial thinning before ablation, and uterine fibroid management before surgery. Prescription-only, clinician-administered as a biodegradable subcutaneous abdominal implant.
Content review status
label verified

Selected public sources

Related tools